key: cord-0950885-r18qujxi
authors: Nazari, Shahrzad; Azari Jafari, Amirhossein; Mirmoeeni, Seyyedmohammadsadeq; Sadeghian, Saeid; Heidari, Mohammad Eghbal; Sadeghian, Siavash; Assarzadegan, Farhad; Puormand, Seyed Mahmoud; Ebadi, Hamid; Fathi, Davood; Dalvand, Sahar
title: Central nervous system manifestations in COVID‐19 patients: A systematic review and meta‐analysis
date: 2021-01-09
journal: Brain Behav
DOI: 10.1002/brb3.2025
sha: 06ed458c2eac082bec0987554ff51f1390a9a46a
doc_id: 950885
cord_uid: r18qujxi

BACKGROUND: At the end of December 2019, a novel respiratory infection, initially reported in China, known as COVID‐19 initially reported in China, and later known as COVID‐19, led to a global pandemic. Despite many studies reporting respiratory infections as the primary manifestations of this illness, an increasing number of investigations have focused on the central nervous system (CNS) manifestations in COVID‐19. In this study, we aimed to evaluate the CNS presentations in COVID‐19 patients in an attempt to identify the common CNS features and provide a better overview to tackle this new pandemic. METHODS: In this systematic review and meta‐analysis, we searched PubMed, Web of Science, Ovid, EMBASE, Scopus, and Google Scholar. Included studies were publications that reported the CNS features between 1 January 2020 and 20 April 2020. The data of selected studies were screened and extracted independently by four reviewers. Extracted data analyzed by using STATA statistical software. The study protocol registered with PROSPERO (CRD42020184456). RESULTS: Of 2,353 retrieved studies, we selected 64 studies with 11,687 patients after screening. Most of the studies were conducted in China (58 studies). The most common CNS symptom of COVID‐19 was headache (8.69%, 95%CI: 6.76%–10.82%), dizziness (5.94%, 95%CI: 3.66%–8.22%), and impaired consciousness (1.90%, 95%CI: 1.0%–2.79%). CONCLUSIONS: The growing number of studies has reported COVID‐19, CNS presentations as remarkable manifestations that happen. Hence, understanding the CNS characteristics of COVID‐19 can help us for better diagnosis and ultimately prevention of worse outcomes.

At the end of December 2019, a novel respiratory syndrome, known as COVID-19, was reported in Wuhan city, Hubei province, China.

The first sign of this infection (2019-nCoV, COVID-19) was pneumonia (Adhikari et al., 2020; WHO, 2020; Shi, Qin, et al., 2020; Velavan & Meyer, 2020; . This new pandemic rapidly spread worldwide, and an increasing number of infected cases and deaths have been reported globally Sohrabi et al., 2020) .

Hence, the COVID-19 outbreak was officially considered as a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) Emergency Committee (Mackenzie & Smith, 2020; WHO, 2020) . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoonotic pathogen and can transmit from infected animals (such as bats and snakes) to humans eventually leading to epidemics and pandemics through human-to-human transmission (Hassan et al., 2020; Mackenzie & Smith, 2020) . Most cases of COVID-19 have shown respiratory symptoms ranging from cough to dyspnea and respiratory failure as well as the typical signs and symptoms of infection such as fever and fatigue (Cascella et al., 2020; Young et al., 2020) .

However, a growing number of COVID-19 patients are presenting with different combinations of the central nervous system (CNS) manifestations (Asadi-Pooya & Simani, 2020; Mao et al., 2020; Montalvan et al., 2020) . Several case reports have indicated the presence of various CNS complications, including encephalitis, stroke, meningitis, and encephalopathy in COVID-19 patients (Co et al., 2020; Filatov et al., 2020; Moriguchi et al., 2020; Zhou, Zhang, et al., 2020) . Furthermore, a large observational study carried out by Mao et al. shows the prevalence of the CNS presentations such as dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure . Therefore, awareness of the different aspects of the short-and long-term effects of this virus on the central nervous system could decently guide scientists.

In this systematic review and meta-analysis, we assessed the CNS manifestations in COVID-19 cases.

We performed this systematic review and meta-analysis based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009) , and our study protocol is submitted to PROSPERO (ID: CRD42020184456). We systematically searched six databases including Google Scholar, Scopus, PubMed, Web of science, Ovid, and EMBASE for all published articles from 1 January 2020 until 20 April 2020 using the following Medical Subject Heading terms (MESH terms):

("Wuhan coronavirus" OR "Wuhan seafood market pneumonia virus" OR "COVID19 virus" OR "COVID-19 virus" OR "coronavirus disease 2019 virus" OR "SARS-CoV-2" OR "SARS2" OR "2019-nCoV" OR "2019 novel coronavirus" OR "2019-nCoV infection" OR "2019 novel coronavirus disease" OR "2019-nCoV disease" OR "coronavirus disease-19" OR "coronavirus disease 2019" OR "2019 novel coronavirus infection" OR "COVID19" OR "COVID-19" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus*") AND ("Manifestation, Neurologic" OR "Neurological Manifestations" OR "Neurologic Manifestation" OR "Neurological Manifestation" OR "Neurologic Symptom" OR "CNS" OR "brain" OR "neuro*" OR "headache" OR "dizziness" OR "ataxia" OR "epilepsy" OR "seizure" OR "migraine*" OR "CSF" OR "Cerebrospinal Fluids" OR "Fluid, Cerebrospinal" OR "Fluids, Cerebrospinal" OR "Cerebro Spinal Fluid" OR "Cerebro Spinal Fluids" OR "Fluid, Cerebro Spinal" OR "Fluids, Cerebro Spinal" OR "Spinal Fluid, Cerebro" OR "Spinal Fluids, Cerebro" OR "stroke" OR "vertigo" OR "consciousness" OR "Impaired consciousness" OR "coma" OR "cerebrovascular disease" OR "acute cerebrovascular disease" OR "encephalitis") alone or in combination with OR and AND operators. Observational studies reported at least one of the related CNS symptoms in COVID-19 patients without any language, race, common CNS symptom of COVID-19 was headache (8.69%, 95%CI: 6.76%-10.82%), dizziness (5.94%, 95%CI: 3.66%-8.22%), and impaired consciousness (1.90%, 95%CI:

1.0%-2.79%).

The growing number of studies has reported COVID-19, CNS presentations as remarkable manifestations that happen. Hence, understanding the CNS characteristics of COVID-19 can help us for better diagnosis and ultimately prevention of worse outcomes.

consciousness disorders, COVID-19, dizziness, headache, nervous system diseases, SARS-CoV-2 infection country, and gender limitations included for quantitative synthesis. The preprint studies, interventional studies, systematic reviews, case reports, conferences, commentaries, letters, editorial, author responses, correspondence articles, in vitro, animal studies, children population, articles without full text, or unreliable data were excluded. In addition, the reference list of the eligible studies was searched to prevent missing publication and include all related literature. The data were independently extracted 

The desired data were recorded using an excel spreadsheet form that included the title, first author, year and month of publication, type of study, country, total sample size, the sample size of male and female, study design, demographic characteristics, exposure history, clinical manifestation, CNS symptoms, and any reported comorbidity.

We 

Data from included studies were extracted for the number of events and total patients to perform a meta-analysis (S.D). Cochrane's Q test and the I 2 index were used to assess heterogeneity among selected studies. Heterogeneity was categorized as low (below 25%), moderate (25%-75%), and high (above 75%) (Higgins & Thompson, 2002) . Also, data adjusted by Freeman-Tukey double arcsine transformation and their 95% CIs were calculated by the Clopper-Pearson method (Clopper & Pearson, 1934) . We calculate mean and standard deviations from median and quartiles by using Wan method (Wan et al., 2014) .

For continuous data, we estimate pooled results of means and their respective 95% CI by the inverse variance method. All analyses were performed using STATA statistical software, version 13 (StataCorp).

As illustrated in (Figure 1 ), a total of 2,353 studies were retrieved after a systematic search in the aforementioned databases. After removing duplicates, 1,760 studies remained. Then, we narrowed the studies to 203 articles by screening with titles and abstracts. In fulltext screening, 45 studies with no reliable or useful data, 24 review articles, 41 preprints, 6 case reports, 1 case controls, 4 reports, 4 papers with specific children population, one study with specific pregnant population, and 13 publications such as Commentary, editorial or Correspondence letters were excluded. Finally, 64 studies (Barrasa et al., 2020; Chen, Qi, et al., 2020; Cheng et al., 2020; Ding et al., 2020; Du, Liu, et al., 2020; Du, Tu, et al., 2020; Feng et al., 2020; Guan et al., 2020; Guo et al., 2020; Gupta et al., 2020; Han et al., 2020; Hsih et al., 2020; Jia et al., 2020; Jin et al., 2020; Kim et al., 2020; Kong et al., 2020; Lei, Huang, et al., 2020; Lei, Jiang, et al., 2020b; Liang et al., 2020; Ling et al., 2020; Liu, Yang, et al., 2020; Liu, Yang, et al., 2020; Liu, Yang, et al., 2020; Lo et al., 2020; Mao et al., 2020; Mi et al., 2020; Mo et al., 2020; Moein et al., 2020; Peng, Liu, et al., 2020; Peng, Meng, et al., 2020; Qian et al., 2020; Qin et al., 2020; Shao et al., 2020; Shi, Han, et al., 2020; Shi, Qin, et al., 2020; Song et al., 2020; Sun et al., 2020; Tan et al., 2020; Tian et al., 2020; Wan, Yi, et al., 2020; Wang, He, et al., 2020; Wang, Fang, et al., 2020; Xu et al., 2020; Yang, Cao, et al., 2020; Yang, Yu, et al., 2020; Yu et al., 2020; Zhang, Cai, et al., 2020; Zhang, Wang, et al., 2020; Zhao et al., 2020; Zheng, Tang, et al., 2020; Zheng, Xu, et al., 2020; Zhong et al., 2020; Zhu et al., 2020) including 11,282 COVID-19 patients, met our inclusion criteria, and were entered in meta-analysis. The main characteristics of our included studies are presented in Table 1 .

The total sample size of eligible studies was 11,687, including 5,568 females and 6,114 males. The mean age for noncritical patients was 48.557 (95% CI: 44.816%-52.299%) and for critical patients was 58.965 (95% CI: 55.792%-62.139%). As shown in Table 2 , the proportion of patients with travel history to Wuhan, Wuhanrelated exposure, and Living in Wuhan was 51.15%, 78.52%, and 47.46%, respectively. In addition, the proportion of patients with travel history to other infected areas and contact with patients was 52.21% and 34.65%, respectively. Mortality was assessed in 25 studies with a pooled incidence rate of 10.47%. The incidence rate of positive females and males was 46.42% (95% CI: 43.01%-49.83%) and 49.50% (95% CI: 45.70%-53.31%), respectively. 36.17% (95% CI:

27.91%-44.84%) of infected patients were in the severe, critical, or intensive care unit condition. In addition, the incidence rate of mortality and survival was 10.47% (95% CI: 5.08%-17.33%) and 81.43% (95% CI: 65.75%-93.29%), respectively.

Based on the results shown in Table 3 and Figure 2 , the most common manifestations were fever 79.39% (95% CI: 73.94%-84.37%), cough 54.77% (95%CI: 49.10%-60.38%), fatigue 32.39% (95% CI: 26.78%-38.0%), dyspnea 28.47% (95% CI: 21.49%-35.99%), chest tightness 23.83% (95% CI: 17.84%-29.82%), and shortness of breath 20.42% (95% CI: 13.28%-28.85%). The highest incidence rate among CNS symptoms of COVID-19 patients was for headache (8.69% with 95% CI: 6.76%-10.82%), followed by dizziness (5.94%, 95%CI: 3.66%-8.22%), and impaired consciousness (1.90% with 95% CI: 1.0%-2.79%). Table 4 shows comorbidities that were reported in 60 studies. The highest incidence rate in comorbidities was hypertension with 23.54% (95% CI: 19.14%-27.94%), diabetes mellitus (11.68% with 95% CI, 9.80%-13.57%), cardiovascular disease (11.66% with 95% CI: 8.97%-14.35%), and cerebrovascular diseases (3.47% with 95% CI: 2.29%-4.85%).

Recently, the world has encountered an emergent outbreak posed by the novel coronavirus 2019, officially known as COVID-19. This infection has become a global threat, endangering millions of lives worldwide. Hence, many experts, researchers, scientists, and clinicians are attempting to investigate various aspects of this new infection to find useful solutions for coping with COVID-19. One of the various aspects of COVID-19 is its impact on the CNS, as reported in a growing number of studies (Baig, 2020) . In addition to the common symptoms in COVID-19, several CNS symptoms such as headache and impaired consciousness have been observed in infected patients .

The process of surveying, screening, and selecting the articles for this systematic review and meta-analysis based on PRISMA guideline TA B L E 1 Demographics and baseline characteristics of included studies with COVID-19-infected patients presenting CNS symptoms reported that the headache may also be related to the elevated level of inflammatory mediators and reduced cerebral blood flow in response to hypoxia (Jasti et al., 2020) , but further studies are needed.

There are two main routes of CNS entry of COVID-19 (hematogenous and peripheral nerves route) leading to CNS infection. In the hematogenous route, the virus infecting respiratory tracts can reach the CNS through the bloodstream via overcoming a strict obstacle known as the blood-brain barrier (BBB) (Desforges et al., 2014 (Desforges et al., , 2020 Román et al., 2020; Sepehrinezhad et al., 2020; Swanson and McGavern, 2015) . They also may enter the CNS through circumventricular organs, those CNS organs lacking the BBB (Chigr et al., 2020) .

The second route, a peripheral nerve, can provide the virus with a retrograde route in to access the CNS via an axonal transport machinery Desforges et al., 2014 Desforges et al., , 2020 Román et al., 2020; Sepehrinezhad et al., 2020; Swanson and McGavern, 2015) . In accordance with this finding, some previous studies on other types of coronaviruses indicate that coronaviruses can reach the brain via cranial nerves (e.g., olfactory, trigeminal nerve terminals in the nasal cavity) (Desforges et al., 2020; Li et al., 2016; Natoli et al., 2020; Netland et al., 2008) .

Furthermore, SARS-CoV-2 can have indirect effects on the CNS (Zhou, Kang, et al., 2020) . Cytokine storm as an immune system response during COVID-19 infection could lead to the breakdown of the blood-brain barrier (BBB) (Liguori et al., 2020; Poyiadji et al., 2020) . Infection of airway tissues by COVID-19 in severe cases leads to impaired gas exchange, subsequently causing CNS hypoxia resulting in neural dysfunction (Abboud et al., 2020) . More precisely, both cytokine storm and hypoxia which are frequently present in the severe condition of infection can contribute to making the BBB more permeable to the virus (Kaur & Ling, 2008; Zhou, Kang, et al., 2020) .

There exists a wealth of evidence that supports the expression and distribution of the ACE2, the receptor for SARS-CoV-2, in the CNS (Jiang et al., 2013; Kawajiri et al., 2009; Xia & Lazartigues, 2008; Xia et al., 2011; Xu et al., 2011; Zubair et al., 2020) .

Hence, ACE2 may be a potential target of COVID-19 upon the entrance into the CNS, triggering its effects on CNS tissue . The presence of the virus in the central nervous system is also supported by some evidence reporting COVID-19 in the CSF of the infected cases (Moriguchi et al., 2020; Zhou, Zhang, et al., 2020) .

In our meta-analysis, the mortality rate of COVID-19 cases with at least one CNS symptom was 10.47%, which is much higher than the mortality rate of the general infected population ( patients. This may be due to the effect of COVID-19 on the brain stem and suppression of the cardiorespiratory control centers causing respiratory failure and death .

Moreover, recent studies have shown that COVID-19 can accelerate the formation of the blood clot in the blood vessels, increasing the risk of cerebrovascular diseases in COVID-19 patients Hess et al., 2020) . Hence, because the brain is nourished with increased severity and mortality . Not only respiratory system dysfunction, but also impairment of respiratory control centers in the CNS (brain stem) can induce acute respiratory failure (Carvalho et al., 2011; Li, Bai, et al., 2020) . Therefore, considering all effective factors, it can provide clinicians to choose the best way in an attempt to manage this pandemic more efficiently.

There are several limitations in our systematic review and metaanalysis. Since in this ongoing pandemic, most of the investigations have conducted on typical signs and symptoms of COVID-19. Thus, the number of studies on the atypical complications of COVID-19, such as CNS presentations, is partially low. Moreover, there exist many COVID-19 preprint papers that have not yet undergone peer review. Additionally, five studies included in our meta-analysis reported headache and/or dizziness as one symptom in COVID-19

cases. Because we were not sure that headache and/or dizziness is resulted from headache or is a consequence of the dizziness, it would be challenging to categorize headache and/or dizziness in the subgroup of dizziness or headache. Hence, in our meta-analysis, it was not reported as a CNS manifestation and is implied as a separate symptom (Table 3) .

COVID-19 is a global problem that currently affects millions of people. This highly pathogenic virus can affect various parts of the human body. Although the respiratory tract has been mainly targeted by COVID-19, the central nervous system can be affected significantly.

In addition, patients with more severe illness showed more CNS symptoms, which may bring on worsen clinical conditions. This study achieved an important estimation for the incidence of neurological 

Dr. Katayoun Alikhani for her supports and comments.

None.

The peer review history for this article is available at https://publo ns.com/publo n/10.1002/brb3.2025.

The data that support the findings of this study are openly available.

Amirhossein Azari Jafari https://orcid. 

COVID-19 and SARS-Cov-2 infection: Pathophysiology and clinical effects on the nervous system

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review

Central nervous system manifestations of COVID-19: A systematic review

Neurological manifestations in COVID-19 caused by SARS-CoV-2

Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria

Novel Coronavirus Infection (COVID-19) in Humans: A scoping review and meta-analysis

Central neurogenic respiratory failure: A challenging diagnosis

Features, evaluation and treatment coronavirus

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

Clinical progression of patients with COVID-19 in Shanghai

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center

The presence of SARS-CoV-2 RNA in Feces of COVID-19 patients

Epidemiological characteristics of novel coronavirus pneumonia in Henan

Comment on "The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients

Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke

The use of confidence or fiducial limits illustrated in the case of the binomial

Intravenous thrombolysis for stroke in a COVID-19 positive Filipino Patient, a case report

Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses

Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis

The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan

Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan

Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study

COVID-19 with different severity: A multi-center study of clinical features

Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus

Spectrum of neurological manifestations in Covid-19: A review

Clinical characteristics of coronavirus disease 2019 in China

Diabetes is a risk factor for the progression and prognosis of COVID-19

Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care Centre in India

Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia

Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment

COVID-19-related stroke

Quantifying heterogeneity in a meta-analysis

Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A review of pathophysiology and neuropsychiatric manifestations of COVID-19

Epidemiological characteristics on the clustering nature of COVID-19 in Qingdao City, 2020: A descriptive analysis

Review of the clinical characteristics of coronavirus disease 2019 (COVID-19)

ACE2-Ang-(1-7)-Mas axis in brain: A potential target for prevention and treatment of ischemic stroke

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Blood brain barrier in hypoxic-ischemic conditions

Angiotensinconverting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis

Clinical Course and outcomes of patients with severe acute respiratory syndrome Coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on. COVID-19

Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea

Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 Novel Coronavirus Pneumonia

Evolution of CT findings in patients with mild COVID-19 pneumonia

Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

Critically ill patients with COVID-19 in Hong Kong: A multicentre retrospective observational cohort study

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia

Chinese Journal of Tuberculosis & Respiratory Diseases

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau

COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don't

Neurologic manifestations of hospitalized patients with coronavirus disease

Characteristics and early prognosis of COVID-19 infection in fracture patients

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Smell dysfunction: a biomarker for COVID-19

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Quality assessment tool for observational cohort and cross-sectional studies

Does SARS-Cov-2 invade the brain? Translational lessons from animal models

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Improved early recognition of coronavirus disease-2019 (COVID-19): Single-center data from a shanghai screening hospital

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features

Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries

COVID-19 virus may have neuroinvasive potential and cause neurological complications: A perspective review

In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Emerging 2019 novel coronavirus (2019-NCoV) pneumonia

Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City

Viral diseases of the central nervous system

C-reactive protein correlates with CT findings and predicts severe COVID-19 early

Characteristics of COVID-19 infection in Beijing

The COVID-19 epidemic

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

General's opening remarks at the media briefing on COVID-19 -11

Coronavirus disease 2019 (COVID-19), 72.Situation Report -72

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Chest CT findings in patients with Coronavirus Disease 2019 and its relationship with clinical features. Investigative Radiology

Angiotensin-converting enzyme 2 in the brain: Properties and future directions

ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function

ACE2/ANG-(1-7)/ Mas pathway in the brain: The axis of good

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

CT scans of patients with 2019 novel coronavirus (COVID-19) pneumonia. Theranostics

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study

Sars-Cov-2: Underestimated damage to nervous system

Understanding the neurotropic characteristics of SARS-CoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms

Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review

Central nervous system manifestations in COVID-19 patients: A systematic review and meta-analysis